PROF

BEARISH

$6.65 Live

Profound Medical Corp. · NASDAQ

Target $11.9 (+78.9%)

$3.76 52W Range $8.95

PROF Profound Medical Corp. - Fundamental Analysis

BEARISH

Console Chart News

PROF Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$6.65

Analyst Target

$11.9

+78.9% Upside

52W High

$8.95

52W Low

$3.76

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$241.35M

P/E

N/A

ROE

-67.1%

Profit margin

-264.4%

Debt/Equity

0.07

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company exhibits strong top-line momentum with 43.10% YoY revenue growth and a healthy gross margin of 70.77%, this is completely offset by a catastrophic profit margin of -264.44%. The company is essentially a high-burn growth play with a very expensive valuation (P/S of 14.99) and a long history of negative earnings. Only the exceptionally high current ratio (12.53) and low debt provide a temporary safety net against insolvency.

Key Strengths

Strong revenue growth (43.10% YoY, 61.32% Q/Q)

High gross margins (70.77%) typical of scalable medical devices

Very low leverage (Debt/Equity 0.07)

Exceptional short-term liquidity (Current Ratio 12.53)

Significant analyst upside potential (Target $11.90)

Key Risks

Severe operational inefficiency (Profit Margin -264.44%)

Critical fundamental health failure (Piotroski F-Score 1/9)

Extreme valuation premium (Price/Sales 14.99)

Chronic inability to achieve profitability over 25 quarters

Bearish technical trend and poor long-term price performance (-66.8% 5Y)

AI Fair Value Estimate

Based on comprehensive analysis

$7.2

+8.3% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Growth

Key drivers: Revenue acceleration, Fundamental health collapse, High cash runway

Confidence

90%

Value

15/100

Ref P/E, PEG, Graham Number

Positives

Low Debt/Equity

Watchpoints

P/S ratio of 14.99 is excessive
Negative P/E
No Graham Number due to lack of earnings

Future

75/100

Ref Growth rates

Positives

Strong YoY and Q/Q revenue growth
High analyst price targets

Watchpoints

Negative EPS growth trends

Past

20/100

Ref Historical trends

Positives

Recent 1Y price recovery (+39.1%)

Watchpoints

5Y return of -66.8%
Consistent quarterly losses

Health

10/100

Ref Altman Z-Score, Piotroski F-Score

Positives

High Current Ratio

Watchpoints

Piotroski F-Score 1/9
Negative ROE/ROA

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$6.65

Analyst Target

$11.9

Upside/Downside

+78.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PROF and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PROF Profound Medical Corp. Primary	-66.8%	-41.5%	+39.1%	+20.2%	+21.6%	+11.8%
CAMP CAMP4 THERAPEUTICS CORPORATION Peer	-56.6%	-56.6%	+78.8%	+41.3%	-25.9%	+5.4%
ALEC Alector, Inc. Peer	-88.2%	-66.9%	+53.9%	-20.0%	+14.6%	+10.0%
CHRS Coherus Oncology, Inc. Peer	-88.2%	-78.7%	+103.2%	-2.3%	-13.5%	-1.2%
MDWD MediWound Ltd. Peer	-51.4%	+35.6%	+6.4%	-3.1%	+6.5%	+6.8%

PRO

Profound Medical Corp.

Primary

-66.8%

-41.5%

+39.1%

+20.2%

+21.6%

+11.8%

CAM

CAMP4 THERAPEUTICS CORPORATION

Peer

-56.6%

+78.8%

+41.3%

-25.9%

+5.4%

ALE

Alector, Inc.

Peer

-88.2%

-66.9%

+53.9%

-20.0%

+14.6%

+10.0%

CHR

Coherus Oncology, Inc.

Peer

-88.2%

-78.7%

+103.2%

-2.3%

-13.5%

-1.2%

MDW

MediWound Ltd.

Peer

-51.4%

+35.6%

+6.4%

-3.1%

+6.5%

+6.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-8.48

N/A

3.63

14.99

11.57

-4.58

$241.35M

Profitability

Profit margins and return metrics

Profit Margin -264.44%

Operating Margin -123.29%

Gross Margin 70.77%

ROE -67.12%

ROA -34.91%

Growth

Revenue and earnings growth rates

Revenue Growth +43.1%

Earnings Growth N/A

Q/Q Revenue Growth +61.32%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.07

Low debt

Current Ratio

12.53

Strong

Quick Ratio

11.02

Excellent

Cash/Share

$1.65

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

66.8%

Op. Margin

-123.3%

Net Margin

-136.8%

Total Assets

$0.1B

Liabilities

$0.0B

Equity

$0.1B

Debt/Equity

0.17x

Operating CF

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

104%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-03-05

$-0.27

+1.2% surprise

2025-11-13

$-0.26

+30.9% surprise

2025-08-14

$-0.52

-30.8% surprise

Healthcare Sector Comparison

Comparing PROF against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)

Return on Equity (ROE)

-67.12%

This Stock

-101.05%

Sector Avg

-33.6% (Below Avg)

Profit Margin

-264.44%

This Stock

-13.75%

Sector Avg

+1822.9% (Superior)

Debt to Equity

0.07

This Stock

3.24

Sector Avg

-97.8% (Less Debt)

Revenue Growth

43.1%

This Stock

121.5%

Sector Avg

-64.5% (Slower)

Current Ratio

12.53

This Stock

4.55

Sector Avg

+175.1% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PROF Profound Medical Corp.	BEARISH	$241.35M	-	-67.1%	-264.4%	$6.65
CAMP CAMP4 THERAPEUTICS CORPORATION	BEARISH	$241.42M	-	-145.1%	-%	$4.65	Compare
ALEC Alector, Inc.	BEARISH	$242.8M	-	-181.6%	-%	$2.2	Compare
CHRS Coherus Oncology, Inc.	NEUTRAL	$250.32M	-	-%	398.4%	$1.67	Compare
MDWD MediWound Ltd.	BEARISH	$226.84M	-	-63.9%	-140.8%	$17.65	Compare

PROF Profound Medical Corp.

BEARISH

Mkt Cap

$241M

P/E

ROE

-67.1%

Price

$6.65

Compare with PROF

Compare with PROF

CHRS Coherus Oncology, Inc.

Compare with PROF

Compare with PROF

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-20	Menawat (Arun Swarup Ph.D.)	Director of Issuer	Acquisition in the public market at price 5.10 per	20,000	$101,920
2025-12-23	Menawat (Arun Swarup Ph.D.)	Director of Issuer	Acquisition in the public market at price 7.46 per	13,396	$100,001
2025-12-23	Rosenthal (Arthur Lee)	Director of Issuer	Acquisition in the public market at price 7.30 per	13,900	$101,470
2025-12-23	Tamberrino (Thomas Michael)	Senior Officer of Issuer	Acquisition in the public market at price 7.19 per	13,908	$99,942
2025-11-24	Ellacott Brian R	Director of Issuer	Option Exercise	719	$4,373
2025-11-24	Lavoie (Cynthia Ph.D.)	Director of Issuer	Option Exercise	719	$4,373
2025-11-24	Lortie (Murielle CPA)	Director of Issuer	Option Exercise	719	$4,373
2025-11-24	Rosenthal (Arthur Lee)	Director of Issuer	Option Exercise	868	$5,280
2025-11-24	Shah (Krishan)	Director of Issuer	Option Exercise	719	$4,373
2025-11-20	Dewan (Rashed Osman)	Senior Officer of Issuer	Option Exercise	1,486	$9,045
2025-11-20	Menawat (Arun Swarup Ph.D.)	Director of Issuer	Option Exercise	4,841	$29,467
2025-11-19	Burtnyk (Mathieu)	Senior Officer of Issuer	Option Exercise	1,486	$9,075

Menawat (Arun Swarup Ph.D.)

Director of Issuer

Acquisi...

2026-03-20

20,000 shares · $101,920

Menawat (Arun Swarup Ph.D.)

Director of Issuer

Acquisi...

2025-12-23

13,396 shares · $100,001

Rosenthal (Arthur Lee)

Director of Issuer

Acquisi...

2025-12-23

13,900 shares · $101,470

Tamberrino (Thomas Michael)

Senior Officer of Issuer

Acquisi...

2025-12-23

13,908 shares · $99,942

Ellacott Brian R

Director of Issuer

Option Exercise

2025-11-24

719 shares · $4,373

Lavoie (Cynthia Ph.D.)

Director of Issuer

Option Exercise

2025-11-24

719 shares · $4,373

Lortie (Murielle CPA)

Director of Issuer

Option Exercise

2025-11-24

719 shares · $4,373

Rosenthal (Arthur Lee)

Director of Issuer

Option Exercise

2025-11-24

868 shares · $5,280

Shah (Krishan)

Director of Issuer

Option Exercise

2025-11-24

719 shares · $4,373

Dewan (Rashed Osman)

Senior Officer of Issuer

Option Exercise

2025-11-20

1,486 shares · $9,045

Menawat (Arun Swarup Ph.D.)

Director of Issuer

Option Exercise

2025-11-20

4,841 shares · $29,467

Burtnyk (Mathieu)

Senior Officer of Issuer

Option Exercise

2025-11-19

1,486 shares · $9,075

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

FORM 8-K

2026-04-16

PROF filed a Form 8-K on April 16, 2026, likely to announce its periodic financial results.

8-K

FORM 8-K

2026-04-14

PROF filed an 8-K on April 14, 2026, likely to announce its annual financial results or the filing of its Form 10-K.

8-K

FORM 8-K

2026-04-01

8-K

FORM 8-K

2026-03-27

8-K

FORM 8-K

2026-03-13

PROF filed a Form 8-K to report a material corporate event, likely the announcement of its annual financial results given the mid-March filing date.

8-K

FORM 8-K

2026-03-10

8-K

FORM 8-K

2026-03-09

10-K

2026-03-05

PROF filed its 10-K annual report on March 5, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. The provided excerpts do not contain specific financial metrics or detailed risk disclosures.

8-K

FORM 8-K

2026-03-05

PROF filed a Form 8-K on March 5, 2026, likely to announce its annual financial results.

8-K

FORM 8-K

2026-02-12

PROF filed a Form 8-K on February 12, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

FORM 8-K

2026-02-12

8-K

FORM 8-K

2026-02-05

8-K

FORM 8-K

2026-01-28

8-K

FORM 8-K

2026-01-15

8-K

FORM 8-K

2026-01-12

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

5 analysts

Lake Street

2026-01-07

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning PROF from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PROF

PROF Profound Medical Corp. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!